Coronavirus disease (COVID-2019) R&D;
On 31 December 2019, WHO was informed of a cluster of cases of pneumonia of unknown cause detected in Wuhan City, Hubei Province of China. The coronavirus disease (COVID-2019) was identified as the causative virus by Chinese authorities on 7 January. As part of WHO’s response to the outbreak, the R&D; Blueprint has been activated to accelerate diagnostics, vaccines and therapeutics for this novel coronavirus.
COVID-19 Public Health Emergency of International Concern (PHEIC)
Global research and innovation forum: towards a research roadmap
On 30 January 2020, following the recommendations of the Emergency Committee, the WHO Director-General declared that the outbreak constitutes a Public Health Emergency of International Concern (PHEIC).
World scientists on COVID-19 met at the World Health Organization’s Geneva headquarters from 11 to 12 February 2020 to assess the current level of knowledge about the new virus, agree on critical research questions that need to be answered urgently, and ways to work together to accelerate and fund priority research that can contribute to curtail this outbreak and prepare for future outbreaks.
-
2019 Novel Coronavirus: Global Research and Innovation Forum: Towards a Research Roadmap/report
pdf, 431kb -
2019 Novel Coronavirus: Overview of the state of the art and outline of key knowledge gaps/slides
pdf, 3.89Mb
Latest reports
Vaccines
-
Draft landscape of COVID-19 candidate vaccines
pdf, 640kb
23 April 2020 -
ToRs – Working Group on vaccine prioritization
pdf, 577kb -
ToRs – Working Group on Target Product Profile
pdf, 459kb -
ToRs – Working Group on Core Protocol
pdf, 418kb -
ToRs – Working Group on vaccines RD for COVID-19
pdf, 469kb -
An international randomised trial of candidate vaccines against COVID-19 – Outline of solidarity vaccine trial
pdf, 436kb
9 April 2020
Recognizing the critical importance to world health of the rapid availability and deployment of effective vaccines against COVID-19, this large, international, multi-site, individually randomized controlled clinical trial will enable the concurrent evaluation of the benefits and risks of each promising candidate vaccine within 3-6 months of it being made available for the trial. -
WHO Target Product Profiles for COVID-19 Vaccines
pdf, 493kb
9 April 2020
This Target Product Profile (TPP) describes the preferred and minimally acceptable profiles for human vaccines for long term protection of persons at high ongoing risk of COVID-19 such as healthcare workers and for reactive use in outbreak settings with rapid onset of immunity. -
Informal consultation on prioritization of candidate vaccines agents for use in novel coronavirus 2019 infection
pdf, 645kb
30 January 2020 -
Overview of the types/classes of candidate vaccines against MERS-CoV
pdf, 608kb -
Overview of the types/classes of candidate vaccines against SARS-CoV
pdf, 576kb -
WHO Consultation on Cross-Reactivity with other coronaviruses
pdf, 526kb
27 January 2020 -
WHO Consultation on Cross-Reactivity with other coronaviruses
24 January 2020 -
Outline of designs for experimental vaccines and therapeutics
pdf, 375kb
17 January 2020
Animal Models
-
ToRs – Working Group – animal models
pdf, 440kb -
WHO ad hoc COVID19 working group summary
pdf, 142kb
4 April 2020 -
WHO ad hoc COVID19 working group summary
pdf, 412kb
20 March 2020
Therapeutics
-
Informal consultation on the role of therapeutics in COVID-19 prophylaxis and post-exposure prophylaxis
pdf, 150kb
16 April 2020 -
Informal consultation on the role of therapeutics in COVID-19 prophylaxis and post-exposure prophylaxis
pdf, 110kb
15 April 2020 -
Informal consultation on the role of therapeutics in COVID-19 prophylaxis and post-exposure prophylaxis
pdf, 150kb
10 April 2020 -
Informal consultation on the role of therapeutics in COVID-19 prophylaxis and post-exposure prophylaxis
pdf, 148kb
9 April 2020 -
ToRs – Working Group therapeutics prioritization
pdf, 630kb - Landscape analysis of candidate therapeutics for COVID-19
- Web base application to analyse clinical trials to evaluate therapeutics for COVID-19
-
Informal consultation on the role of prophylaxis and post-exposure prophylaxis
pdf, 565kb
Teleconference notes 31 March 2020 -
Informal consultation on the role of IL-6/IL-1.
pdf, 555kb
Teleconference notes 25 March 2020 -
Informal consultation on the role of therapeutics in COVID 19 prophylaxis and post-exposure prophylaxis
pdf, 635kb
18 March 2020 -
Informal consultation on the potential role of chloroquine in the clinical management of COVID 19 infection
pdf, 481kb
13 March 2020 -
COVID-19 Therapeutic Trial Synopsis
pdf, 895kb
18 February 2020 -
Outline of trial designs for experimental therapeutics
27 January 2020 -
Informal consultation on prioritization of candidate therapeutic agents for use in novel coronavirus 2019 infection
24 January 2020 -
Outline of designs for experimental vaccines and therapeutics
21 January 2020 -
Outline of designs for experimental vaccines and therapeutics
20 January 2020 -
Overview of the types/classes of candidate therapeutics
pdf, 921kb
Ethics
Diagnostics
Scientific Advisory Group
Global Coordination Mechanism
-
GCM teleconference on Pneumonia of unknown etiology in Wuhan, China – Note for the Records
pdf, 89kb
20 January 2020 -
GCM teleconference on Pneumonia of unknown etiology in Wuhan, China – Note for the Records
pdf, 333kb
10 January 2020